Humana Inc. (NYSE:HUM) had its price target cut by Morgan Stanley from $276.00 to $270.00 in a research report report published on Thursday morning. They currently have an overweight rating on the insurance provider’s stock.

HUM has been the subject of several other reports. ValuEngine lowered Humana from a buy rating to a hold rating in a research report on Tuesday, October 10th. BidaskClub upgraded Humana from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Jefferies Group LLC reiterated a hold rating and set a $257.00 price objective on shares of Humana in a report on Friday, October 13th. J P Morgan Chase & Co cut Humana from an overweight rating to a neutral rating and set a $253.00 price objective on the stock. in a report on Monday, October 9th. Finally, Royal Bank Of Canada reiterated a hold rating and set a $245.00 price objective on shares of Humana in a report on Tuesday, October 10th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $252.81.

Humana (NYSE HUM) traded down $3.07 during trading on Thursday, hitting $244.39. The stock had a trading volume of 1,265,400 shares, compared to its average volume of 1,376,685. The firm has a market cap of $34,913.58, a price-to-earnings ratio of 20.85, a P/E/G ratio of 1.68 and a beta of 0.91. Humana has a 52 week low of $186.25 and a 52 week high of $264.56. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.27 by $0.12. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.18 EPS. equities research analysts expect that Humana will post 11.64 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Humana Inc. (HUM) Price Target Cut to $270.00 by Analysts at Morgan Stanley” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/11/13/humana-inc-hum-price-target-cut-to-270-00-by-analysts-at-morgan-stanley.html.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is presently 12.59%.

In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now directly owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Timothy S. Huval sold 7,803 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the transaction, the vice president now directly owns 8,831 shares in the company, valued at $2,279,634.34. The disclosure for this sale can be found here. Insiders have sold a total of 20,660 shares of company stock worth $5,319,600 over the last three months. 0.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. WFG Advisors LP grew its holdings in shares of Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after purchasing an additional 20 shares in the last quarter. Acrospire Investment Management LLC acquired a new stake in shares of Humana during the 2nd quarter worth $120,000. Independent Portfolio Consultants Inc. grew its holdings in shares of Humana by 22.1% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after purchasing an additional 94 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Humana by 139.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after purchasing an additional 325 shares in the last quarter. Finally, Fiduciary Trust Co. bought a new stake in shares of Humana during the 2nd quarter worth $135,000. 96.15% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.